

Resource Summary Report

Generated by [RRID](#) on Aug 15, 2026

University of Michigan Rogel Cancer Center Immune Monitoring Core Facility

RRID:SCR_025765

Type: Tool

Proper Citation

University of Michigan Rogel Cancer Center Immune Monitoring Core Facility
(RRID:SCR_025765)

Resource Information

URL: <https://www.rogelcancercenter.org/research/shared-resources-and-cores/immunologic-monitoring>

Proper Citation: University of Michigan Rogel Cancer Center Immune Monitoring Core Facility (RRID:SCR_025765)

Description: Provides immunologic and biological support for ongoing research projects and clinical trials. Services include measuring multiple cytokines in single assay, determining cytokine concentrations in various biological specimens and monitoring immune cell activation through investigative analytic procedures. Offers sample processing expertise for blood and tissue samples, including both plasma or serum and peripheral bloodmononuclear cells.

Synonyms: University of Michigan Rogel Cancer Center Immune Monitoring Core, University of Michigan Rogel Cancer Center Immune Monitoring Shared Resource

Resource Type: service resource, access service resource, core facility

Keywords: measuring multiple cytokines, research projects and clinical trials, determining cytokine concentrations, monitoring immune cell activation, sample processing,

Availability: Restricted

Resource Name: University of Michigan Rogel Cancer Center Immune Monitoring Core Facility

Resource ID: SCR_025765

Record Creation Time: 20240920T053257+0000

Record Last Update: 20260815T042944+0000

Ratings and Alerts

No rating or validation information has been found for University of Michigan Rogel Cancer Center Immune Monitoring Core Facility.

No alerts have been found for University of Michigan Rogel Cancer Center Immune Monitoring Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Molecular cancer therapeutics, 24(6), 843.